A Study of Belantamab Alone and in Combination With Other Treatments in People With Multiple Myeloma

Full Title

A Phase 1/2 Open Label Multicentre Dose Escalation and Expansion Study to Investigate the Safety, Tolerability and Clinical Activity of Belantamab as Monotherapy and in Combination with other Treatments in Participants with Multiple Myeloma

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Hamza Hashmi’s office at 646-608-4348. 

Protocol
26-383
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Hamza Hashmi
Co-Investigators
Saad Z. Usmani
Diseases
Hematology › Multiple Myeloma
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT05714839
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description